Thematic review series: The Immune System and Atherogenesis. The unusual suspects:an overview ofthe minor leukocyte populations in atherosclerosis by Paul A. VanderLaan, Catherine A. Reardon

Get full text

VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice*[S] by Paul A. VanderLaan, Catherine A. Reardon, Ronald A. Thisted, Godfrey S. Getz

Get full text

The impact of pathology grossing protocol measures to improve pathologic nodal staging in lung cancer by Robert Ta, Gracijela Bozovic, Jennifer L Wilson, Alexander A Bankier, Paul A VanderLaan

Get full text

Pulmonary amyloidosis as the presenting finding in a patient with multiple myeloma by Ryan Kronen, David R. Ziehr, Ashley E.D. Kane, Paul A. VanderLaan, Cyrus A. Kholdani, Robert W. Hallowell

Get full text

A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into... by Hollis Viray, Andrew J. Piper-Vallillo, Page Widick, Emmeline Academia, Meghan Shea, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa

Get full text

An Unusual Cause of Functional Mitral Stenosis by Jamie E. Diamond, MD, MPH, Michael Y. Mi, MD, Paul A. VanderLaan, MD, PhD, Louis Chu, MD, Eli V. Gelfand, MD

Get full text

CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in <i>Ldlr^−/−</i> Mice by Tapan K. Biswas, Paul A. VanderLaan, Xuchu Que, Ayelet Gonen, Paulette Krishack, Christoph J. Binder, Joseph L. Witztum, Godfrey S. Getz, Catherine A. Reardon

Get full text

Massive Thymic Hyperplasia Masquerading as Cancer: A Case Report and Review of the Literature by Emily Stern Gatof, MD, Sarmad H. Jassim, MD, Leah Ahn, MD, Zsu-Zsu Chen, MD, Paul A. VanderLaan, MD, PhD, Deepa Rangachari, MD

Get full text

CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma. by Yi Cai, Ayako Hirata, Sohei Nakayama, Paul A VanderLaan, Elena Levantini, Mihoko Yamamoto, Hideyo Hirai, Kwok-Kin Wong, Daniel B Costa, Hideo Watanabe, Susumu S Kobayashi

Get full text

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors by Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Get full text

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene by Zachary R. Schoepflin, MD, Emmeline Academia, PharmD, Soravis A. Osataphan, MD, Deepa Rangachari, MD, Sheida Sharifi, MD, PhD, Paul A. VanderLaan, MD, PhD, Daniel B. Costa, MD, PhD

Get full text

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors by Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Get full text